IN8bio Inc Sustainability Reports
IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its programs primarily target solid and liquid tumors, including glioblastoma and leukemia, through drug-resistant immunotherapy platforms.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 549300H68IVCRKSGSL94
1 reports from 2023 to 2023
Company Profile
IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its programs primarily target solid and liquid tumors, including glioblastoma and leukemia, through drug-resistant immunotherapy platforms.
Reports
1 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
Years
